Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Behav Brain Res. 2015 Mar 21;287:89–95. doi: 10.1016/j.bbr.2015.03.023

Figure 2. FST antidepressant-like effects of Ro 25-6981 in NMDAR, AMPAR and PSD-95 loss-of-function mutants.

Figure 2

(A) Systemic Ro 25-6981 reduced FST immobility in C57BL/6J mice, relative to vehicle (n=6 per treatment). (B) In GluN1INTER-KO mutant mice, Ro 25-6981 decreased FST immobility regardless of genotype (n=12 per genotype/treatment). (C) Ro 25-6981 decreased FST immobility in WT controls but not GluN2AKO mutant mice, and vehicle-treated mutants were less immobile than vehicle-treated WT controls (n=10–14 per genotype/treatment). (D) In GluA1KO mutant mice, Ro 25-6981 decreased FST immobility regardless of genotype, and mutants were less immobile than WT controls (n=6 per genotype/treatment). (E) Ro 25-6981 decreased FST immobility in WT controls but not PSD-95KO mutant mice, and vehicle-treated mutants were less immobile than vehicle-treated WT controls (n=5–6 per genotype/treatment). Veh=vehicle, Ro=Ro 25-6981. Data are means ± SEM. *P<.05 Ro versus Veh, #P<.05 KO versus WT